High efficacy of glecaprevir/pibrentasvir for HCV-infected individuals with active drug use: Some issues

J Infect. 2022 Oct;85(4):e94-e95. doi: 10.1016/j.jinf.2022.07.004. Epub 2022 Jul 8.

¹ Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Biological Science and Technology, College of Biological Science and Technology, National Yang Ming Chiao Tung University, Hsinchu, Taiwan.
² Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
³ Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Biological Science and Technology, College of Biological Science and Technology, National Yang Ming Chiao Tung University, Hsinchu, Taiwan. Electronic address: fish6069@gmail.com.tw.

No abstract available

Keywords: DAA; Glecaprevir; HCV; Pibrentasvir.

Publication types